Phillip Walker
Research Subjects
Phillip Walker has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Emil Lou
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA
96 shared publications - Joanne Xiu
Caris Life Sciences, Phoenix, Arizona, USA
72 shared publications - Andrew Elliott
Caris Life Sciences, Phoenix, USA
67 shared publications - Wolfgang Michael Korn
Caris Life Sciences, Phoenix, USA
56 shared publications - Abderrahman Day
Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota
43 shared publications - Allison Makovec
Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA
43 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Tumor mutation burden (muts/Mb) of ATM and BRCA2 mutant mPCs.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Tumor mutation burden (muts/Mb) of ATM and BRCA2 mutant mPCs.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Overall survival of ATM, BRCA2 mutant, and HRDother mPCs.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Overall survival of ATM, BRCA2 mutant, and HRDother mPCs.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Comparisons of WTS profiles between ATMm and BRCA2m to the HRP group.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Comparisons of WTS profiles between ATMm and BRCA2m to the HRP group.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Composition and rates of all detectable genomic features detectable through the Caris diagnostic platform.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Composition and rates of all detectable genomic features detectable through the Caris diagnostic platform.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
AR activities and NEPC signatures in ATM- and BRCA2- mutated tumors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
AR activities and NEPC signatures in ATM- and BRCA2- mutated tumors.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Figure S6 and legend
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Figure S6 and legend
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Figure S7 and legend
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Figure S7 and legend
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Table S1 from XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
Supplementary Table S1 from XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance